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The RNA/DNA-binding protein, TDP-43, is the key component of ubiquitinated inclusions characteristic of amyotrophic
lateral sclerosis (ALS) and the majority of frontotemporal lobar degeneration (FTLD-TDP) referred to collectively as
TDP-43 proteinopathies. To further elucidate mechanisms of pathological TDP-43 processing and identify TDP-43
epitopes that could be useful as potential biomarkers of TDP-43 proteinopathies, we developed a panel of novel
monoclonal antibodies (MAbs) directed at regions extending across the length of TDP-43. Here, we confirm previous
observations that there is no or minimal accumulation of TDP-43 N-terminal domains in neocortical inclusions in
human TDP-43 proteinopathy tissues and we identify a subset of these MAbs that are specific for human versus
mouse TDP-43. Notably, one of these MAbs recognized an epitope that preferentially detected pathological TDP-43
inclusions with negligible reactivity for normal nuclear TDP-43 resembling anti-phospho-TDP-43 specific antibodies
that only bind pathological TDP-43. Hence, we infer that this new MAb recognizes a phosphorylation independent
but disease-specific pathologic conformation in abnormal TDP-43. These data suggest that the novel MAbs
reported here will be useful for patient-oriented research as well as for studies of animal and cell-based models
of TDP-43 proteinopathies including ALS and FTLD-TDP.
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Since the landmark discovery of the RNA/DNA binding
protein, TDP-43, as the main constituent of ubiquitin-
positive, tau/synuclein-negative inclusions in amyotrophic
lateral sclerosis (ALS) and frontotemporal lobar degen-
eration (FTLD) referred to as FTLD-TDP [1], there have
been numerous advances in our understanding of these
seemingly disparate clinical and neuropathological syn-
dromes (reviewed in [2]). Indeed, ALS and FTLD-TDP
are now considered to be different manifestations along
a continuum or spectrum of TDP-43 proteinopathies [3].
Further, hierarchical non-random progression of TDP-43
pathology in ALS [4] and FTLD-TDP [5] suggest potential
neuron-to-neuron spread of TDP-43 as a major driving
force in the progression of the neurodegenerative process.
Indeed, cell culture experiments suggest the possibility* Correspondence: vmylee@upenn.edu
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unless otherwise stated.of transmission of pathological TDP-43 between cells
[6] similar to those reported in animal and cellular
models of tauopathies [7,8] and Parkinson’s disease [9-12].
Accordingly, strategies to prevent or slow the transmission
of pathogenic forms of TDP-43 in affected patients with
passive immune therapy using disease specific monoclonal
antibodies (MAbs) to pathological TDP-43 could emerge
as a major therapeutic approach for treatment of FTLD-
TDP and ALS. To that end and for future research on
animal- and cell-based models of TDP-43 proteinopathies,
well-characterized MAbs to normal and pathological
epitopes in TDP-43 are urgently needed. Here we describe
the generation and characterization of novel MAbs that
detect normal and disease-specific epitopes spanning the
length of TDP-43.Materials and methods
Recombinant TDP-43 production
Human recombinant TDP-43 (rTDP-43) proteins includ-
ing full length TDP-43 (FL-rTDP-43), i.e. amino acids (aa)
1–414, N-terminally truncated TDP-43 (Nt-rTDP-43), aaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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aa 182–414 were expressed in BL21 (DE3) E. coli cells
using the pCOLD vector system (Takara Bio Inc., Japan).
TDP-43 proteins were extracted from E. coli 16 h after
IPTG induction, and the vast majority of the rTDP-43
proteins were present in inclusion bodies. The bacterial
pellet was sequentially extracted with PBS and 1% Triton
X-100 to remove soluble bacterial proteins. For immuniza-
tion, the Triton X-100 insoluble rTDP-43 was solublized
with 1% Sarkosyl buffer or 4 M urea. Sarkosyl was removed
by exhaustive dialysis before use. For epitope mapping, the
Triton X-100 insoluble rTDP-43 was solublized directly in
Laemmli sample buffer, and immunoblot (IB) analysis was
done as described previously [13,14].
MAb generation and screening
Murine MAbs were raised against human rTDP-43 pro-
teins using similar methods described previously [15-18].
Mice were immunized with FL-rTDP-43 or Nt-rTDP-43.
Briefly, rTDP-43 proteins were emulsified with Freund’s
adjuvant and injected subcutaneously into BALB/c mice.
The mice were boosted 3 additional times at 2 week
intervals. Three days prior to harvesting spleens for
fusion to generate MAbs, the mice received intraperi-
toneal injection of rTDP-43 without adjuvant. Splenic
lymphocytes were fused to Sp2 mouse myeloma cells
using the polyethylene glycol method to produce mouse
hybridomas as described [15]. Animal care and all proce-
dures performed here were conducted in accordance with
the NIH Guide for the Care and Use of Experimental
Animals and approved by the University of Pennsylvania
Institutional Animal Care and Use Committee. Hybridoma
supernatants were initially screened for the ability to
recognize human FL-rTDP-43 by indirect enzyme-linked
immunosorbant assay (ELISA), and positive clones were
further evaluated by IB using FL-rTDP-43 and by im-
munohistochemistry (IHC) on formalin and ethanol fixed
paraffin-embedded sections of FTLD-TDP cortex (see
below). Cells from positive hybridomas were expanded
and re-screened as above.
Epitope mapping and characterization of MAbs
The TDP-43 domains harboring the epitopes recognized
by these new MAbs were first estimated using FL-rTDP-
43, Nt-rTDP-43 and Ct-rTDP-43 in IB studies similar to
our characterization of MAbs we previously generated
to tau and alpha-synuclein [18,19]. After probing with
the MAbs, the bound antibodies were detected with
horseradish peroxidase-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA). The blots
were visualized using the chemiluminescent system as
described previously [1]. For more refined mapping of the
TDP-43 protein domains harboring the epitopes detected
by these MAbs, indirect ELISAs were performed usingpeptides corresponding to different regions spanning the
length of TDP-43: aa 6–24, 40–54, 110–147, 175–187,
189–195, 203–220, 235–243, 251–263, 287–322, 341–352,
and 394–414. Cross-reactivity to mouse TDP-43 was eval-
uated by IB using RIPA solubilized human and mouse
cell lysates [20] and by IHC using paraffin-embedded
mouse and human brain sections (see below). To determine
human specificity, the immunoreactivity of each MAb to
human versus mouse TDP-43 was compared as described
by Giasson et al. [19]. Similarly, immunocytochemistry
(ICC) was performed using QBI293 and Neuro2a cells
to verify cross-reactivity [20]. Human cortical urea extracts
from a normal control and a FTLD-TDP case were used
to determine if the MAbs recognized the pathological
signature of TDP-43 by IB [1]. Isotypes of the MAbs were
determined using a commercial rapid ELISA mouse anti-
body kit (Thermo Fisher Scientific, Rockford, IL, USA).
Sandwich ELISA
The 384-well format sandwich ELISA method used to
evaluate the MAbs was similar to those described previ-
ously for a 96-well format, except the sample volumes
used were reduced to 30 μL/well [21]. Briefly, plates were
coated with 5 μg/mL of capture antibody (rabbit polyclonal
Ct or Nt TDP-43 (pAb) or MAbs) and incubated overnight
at 4°C. Plates were blocked for a minimum of 3 days at
4°C with Block-Ace (AbD Serotec, Raleigh, NC). After
the blocking solution was removed, 0, 1 or 10 ng/mL of
FL-rTDP-43 were added to wells and incubated for 16 h
at 4°C. Plates were subsequently washed and incubated
with 0.2, 1 or 10 μg/mL, detection antibody (MAbs for the
rabbit pAb coated plates and rabbit pAb for MAb coated
plates) for 16 h at 4°C. The plates were then washed
and incubated with HRP-conjugated reporting antibodies
(goat anti-mouse or anti-rabbit, respectively), for 1 h at
25°C (Santa Cruz Biotechnology). A tetramethyl benzidine
peroxidase substrate system was used for the color de-
velopment step (Thermo Fisher Scientific, Rockford, IL,
USA). A serial diluted rTDP-43 standard curve, 10 ng/mL
to 1 pg/mL, was used to estimate the level of detergent
soluble TDP-43 in brain tissue or cell extracts. Samples
were done in quadruplicates. Detection limit is defined as
average optical density of reagent background (no rTDP-
43 added) plus 4 times the standard deviation.
IHC studies
Human CNS tissues from the superior temporal cortex
(FTLD-TDP subtypes A-D) and spinal cord (ALS) (one
patient each) were examined to evaluate the reactivity of
TDP-43 MAbs in pathological aggregations and neuronal
nuclei (for demographic details please see Additional
file 1: Table S1). Neuropathological examination of human
cases was performed as described previously [22] using
current neuropathological criteria for the diagnosis of
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tissues were obtained at autopsy and processed following
standard established protocol [22]. Autopsy and required
informed consent were performed in accordance with
the University of Pennsylvania Institutional Review Board.
Paraffin-embedded human CNS tissue sections were
deparaffinized in xylenes and rehydrated in a descend-
ing series of ethanol. Endogenous peroxidases were blocked
with 5% hydrogen peroxide in methanol, and sections were
microwaved in 1% antigen unmasking solution (Vector
Laboratories, Burlingame, CA) at 99°C for 15 min, blocked
in 2% fetal bovine serum in 0.1 M Tris buffer and incu-
bated with TDP-43 MAbs in ascites or as purified IgG.
Affinity-purification of IgG was done using the HiTrap
Protein G column according to manufacturer instructions
(GE Healthcare, Piscataway, NJ). MAbs were incubated
overnight at 4°C at concentrations of 1:1 K-1:100 K (asci-
tes) or 0.03-1.0 μg/ml (purified IgG). Reactivity of novel
TDP-43 MAbs was compared with a previously charac-
terized disease-specific MAb to TDP-43 phosphorylated at
serine 409 and 410 (MAb p409/410) [25] at concentra-
tions of 1:250–1:500.
IHC of mouse CNS tissues was performed in the same
manner described above, and in addition, we used a mouse
on mouse (MOM) immunodetection kit (Vector Labora-
tories) to minimize endogenous mouse IgG background.
For all sections, labeling was detected using species-specific
biotinylated secondary antibodies incubated for 1 h and
the Vectastain ABC kit followed by the ImmPACT™ DAB
Substrate kit (Vector Laboratories). Slides were cover-
slipped with CytoSeal 60 mounting medium (Thermo
Scientific).
The degree of non-pathological nuclear TDP-43 and
pathological TDP-43 deposits in human lower motor
neurons (LMN), white-matter glial cell inclusions (GCI),
neuronal cytoplasmic inclusions (NCI), dystrophic neur-
ites (DN) and neuronal nuclear inclusions (NII) were
reviewed by a trained examiner (DJI) and rated on a semi-
quantitative scale (0 = none, r = rare, + = few, ++ =moder-
ate, +++ =many) for each MAb. Digital images of IHC
results were obtained using an Olympus BX 51 micro-
scope equipped with a bright-field and fluorescence light
source with a DP-71 digital camera (Olympus; Center
Valley, PA) and DP manager software (Olympus).
Results
MAb generation and epitope mapping
To gain further insights into the molecular and neuro-
pathological roles of TDP-43 in neurodegeneration, we
generated new MAbs for future studies of TDP-proteino-
pathies. Approximately 4500 potential MAb clones from
three hybridoma fusion procedures were screened by
FL-rTDP-43 indirect ELISA of which 168 clones were
positive on this initial screen and all were evaluatedfurther in IB and IHC studies. Only 45 clones continued
to show immunoreactivity toward TDP-43 in the second-
ary screens and all of these MAbs were studied further
to determine the epitopes and their antibody isotype as
described [18,19]. Using FL-rTDP-43, Nt-rTDP-43, and
Ct-rTDP-43 for IB analyses, the epitope region was
estimated to be within aa 1–181 for 6 MAbs, within aa
182–261 for 5 MAbs, and within aa 262–414 for 34
MAbs (data not shown and Table 1). Indirect ELISA
using a panel of TDP-43 peptides as antigens further
mapped some of the epitopes to smaller regions of TDP-
43. Four of the MAbs recognized the aa 6–24 peptide, 7
recognized the aa 289–322 peptide and 3 recognized the
extreme C-terminus peptide (aa 394–414) (Figure 1). After
additional cell passages and/or subcloning procedures, 18
MAbs were selected for further characterization based on
the hybridomas’ apparent clonality and stability. These
MAbs were shown to have their putative epitopes mapped
to the regions in TDP-43 shown in Table 1. Next, these
MAbs were evaluated for their effective use in several
assays including: immunoprecipitation and IB of human
cell lysates, IHC, ICC, and sandwich ELISA. Most of
the MAbs were found to have efficacy in all assays tested,
except for MAb 211 (Table 1) which failed as a detection
antibody by ELISA even at a 20 fold higher concentration
than that used for other MAbs (data not shown).
To determine whether or not the selected 18 MAbs
detected both human and mouse TDP-43, IHC was per-
formed using normal human and non-transgenic mouse
brain sections. All 18 MAbs detected nuclear TDP-43
in sections of human hippocampus (Figure 2a,c), but 7
of these MAbs did not detect mouse TDP-43 by IHC
(compare Figure 2b to Figure 2d). To determine if these 7
apparently human specific MAbs detect mouse TDP-43 in
other applications, we compared their immunoreactivity
toward human versus mouse TDP-43 from cultured cells
on IB. Only 3 of these 7 MAbs (138, 5123, and 5104) did
not detect the mouse protein. The remaining 4 MAbs,
including MAbs 5032 and 5095, recognized mouse TDP-
43, albeit with lower efficiency than the human protein
(Figure 2e). Thus, we identified 11 MAbs that detected
both mouse and human TDP-43 with equal affinity, 4
that preferentially recognized human versus mouse TDP-
43 but were not completely human specific, and 3 that
detected human but not mouse TDP-43 in the assays
used here.
ELISA studies
As of now, there is no reliable method to quantify TDP-43
proteins in biofluids such as plasma or cerebrospinal fluid
(CSF) samples which would be useful as a biomarker
assay. In order to determine if the MAbs generated in
this study might be useful for developing an assay to
detect TDP-43 in CSF or plasma, we evaluated them in
Table 1 Summary of the characterization of New TDP-43 MAbs
MAb Isotype Epitope (aa) IP IB IHC ICC ELISA capture ELISA detect Human preference
211 IgG1 6-24 - + + + + - -
5031 IgG2a 25-181 + + + + + + -
138 IgG2a 182-261 + + + + + + +
5060 IgG2a 182-261 ND + + + + + -
5117 IgG2a 287-322 ND + + + + + -
5156 IgG2a 287-322 + + + + + + -
205 IgG2a 262-391 + + + + + + +
241 IgG1 262-391 + + + + + + +
5028 IgG1 262-391 + + + + + + -
5032 IgG1 262-391 + + + + + + +
5053 IgG1 262-391 ND + + - + + -
5056 IgG2a 261-391 + + + + + + -
5089 IgG2b 261-391 + + + + + + -
5095 IgG1 261-391 + + + + + + +
5104 IgG1 261-391 + + + + + + +
5123 IgG1 261-391 + + + + + + +
5101 IgG1 261-391 + + + + + + -
5195 IgG2a 394-414 + + + + + + -
This table summarizes the properties the new MAbs described here. New abbreviation: ND = not determined.
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Ct-TDP-43 pAbs [17] as capture or detection antibody.
As mentioned above and shown in Table 1, 17 MAbs
were capable of detecting and capturing FL-rTDP-43 by
ELISA. This suggested that one or more of these MAbs
may be advanced for the development of a sensitive ELISA
to quantify TDP-43, especially in biofluids. This is exem-
plified by studies using MAb 205 for capture and the
Ct-pAb as the detection antibody in an ELISA that
showed a lower limit of detection for human rTDP-43
of ~25 pg/mL (see Additional file 1: Figure S1). Using this
sensitive ELISA, we were able to quantify the amount of
detergent soluble TDP-43 in QBI293 cell lysates and in hu-
man FTLD-TDP cortical grey matter lysates, ~30 ng/mg
protein and ~850 ng/g grey, respectively.Figure 1 Schematic representation of TDP-43 domains containing epi
harboring the epitopes recognized by 45 newly generated MAbs were mapp
and indirect peptide ELISA and the putative amino acid stretches included in
RRM: RNA-recognition motif; NLS: bipartite nuclear localization signal; NES: nuImmunoreactivity in human tissue
TDP-43 MAbs were screened for reactivity in human CNS
tissues using IHC in the spinal cord of ALS and superior
temporal cortex of morphological subtypes of TDP-43
(Type A-D) [24]. Semi-quantitative analyses for each
type of morphologic inclusion (i.e. LMN, NCI, DN, NII,
and GCI) in ALS and FTLD-TDP are summarized in
Table 2. MAbs 211 and 5031, which are specific for the
N-terminus of TDP-43 (i.e. regions A and B as illustrated
in Figure 1) showed robust reactivity for normal nuclear
TDP-43, but 5031 detected more pathology in the ALS
spinal cord and FTLD-TDP temporal cortex than 211
(Figure 3a,c and data not shown). Indeed, the amount of
pathologic TDP-43 in cortical sections detected by 5031
was modest, while 211 did not detect significant amountstopes recognized by the MABs reported here. The TDP-43 domains
ed to regions along the entire length of TDP-43 (A-F) by immunoblot
these epitopes is depicted in the table to the right of the schematic.
clear export signal.
Figure 2 Representative IHC staining patterns and immunoblot profiles of selected MAbs that recognize human- or human- and
mouse-TDP-43. MAb 5195 detects normal nuclear TDP-43 in (a) human and (b) mouse hippocampus dentate gyrus. In contrast, MAb 5095
detects (c) human but not (d) mouse TDP-43, which is representative of 7 MAbs that preferentially recognize human TDP-43. Scale bar = 50 μm.
(e) All the MAbs here show strong immunoreactivity with a 43 kDa band from human cell lysates, but 7 MAbs preferentially recognize human
TDP-43 with little or no detection of mouse TDP-43. MAb clone numbers are shown above each immunoblot, and MAb 5195 is representative of
8 MAbs that detect human and mouse TDP-43 with equal affinity. H – human, M – mouse.
Kwong et al. Acta Neuropathologica Communications 2014, 2:33 Page 5 of 9
http://www.actaneurocomms.org/content/2/1/33of neocortical TDP-43 deposits in the FTLD-TDP cases.
Thus, the N-terminal specific MAbs preferentially detected
TDP-43 pathology mainly in spinal cord motor neurons,
which contains a predominance of full-length TDP-43 [13].
In contrast, MAbs specific for the RNA recognition motif
2 (RRM2), i.e. Region C in Figure 1 or the C-terminal
glycine rich domain (i.e. Regions D-F) were immunore-
active to all forms of neocortical pathological TDP-43
inclusions seen in FTLD-TDP subtypes, as well as LMN
inclusions in ALS from a moderate to high degree for
most inclusion types (Figure 3b,d). The minimal limited
immunoreactivity of MAbs specific for N-terminal regions
in neocortical TDP-43 inclusions of FTLD-TDP cases was
confirmed using IB analyses of human CNS urea extract
of FTLD-TDP brains which showed that a C-terminal
fragment (CTF) of TDP-43 was detected by MAbs specific
for regions in the C-terminus (Figure 3f ), but not the
N-terminus specific MAb 5031 (Figure 3e). Moreover,
MAb 5031 also did not detect the pathological hyper-
phosphorylated 45 kD band or the high molecular weight
(MW) smears which were detected MAb 5056, consistent
with previous findings [13].
The reactivity to neocortical TDP-43 pathology by MAbs
specific for C-terminal TDP-43 epitopes was accompanied
by a moderate to high reactivity for normal nuclear
TDP-43 by all MAbs except MAb 138. MAb 138,which is specific for region C in the RRM2, displayed
high reactivity to pathological TDP-43 deposits similar
to other TDP-43 MAbs specific for Regions C-F, in the
absence of significant normal nuclear TDP-43 staining
(Figure 4). This preferential detection of pathological TDP-
43 inclusions with minimal or no normal nuclear TDP-43
staining by IHC is similar to the staining pattern seen with
pathology-specific phospho-TDP-43 specific MAbs such
as the p409/410 MAb mentioned above. There was no
regional predilection for this pattern, as it was evident
in both the neocortex and spinal cord of ALS and
FTLD-TDP patients. To further test this observation we
analyzed the hippocampal dentate gyrus from a non-
neurodegenerative control case with MAb138 under a
range of dilutions to establish if the negligible degree
of normal nuclear TDP staining was reproducible in a
control case. As shown in Online Resource 1 (Additional
file 1: Figure S2), the pattern of immunoreactivity ob-
served with MAb 138 did not appear to reflect antibody
dilution or affinity. Finally, there were no clear differences
between the ability of the different MAbs to detect the dif-
ferent morphological types of TDP-43 inclusions (i.e. DN,
NCI, NII, GCI and granular cytoplasmic TDP deposits),
FTLD-TDP subtypes A-D as classified by MacKenzie et al.
[24] or clear effects of fixative method or post-mortem
interval in this screening survey.
Table 2 IHC properties of new TDP-43 MAbs
Region/
antibody
Spinal cord Temporal cortex
Nuclei LMN GCI Nuclei NCI DN NII GCI
A (aa 6–24)
211 +++ + + +++ 0 0 0 0
B (aa 25–181)
5031 ++ +++ + ++ r + + r
C (aa 182–261)
138 0 +++ + 0 +++ ++ + +
5060 +++ +++ + ++ + + ++ r
D (aa 287–322)
5117 ++ ++ r +++ +++ ++ r ++
5156 +++ +++ r +++ +++ +++ + ++
E (aa 262–391)
205 +++ +++ r ++ +++ ++ + +
241 ++ +++ + ++ +++ ++ + +
5053 +++ +++ + +++ +++ +++ ++ +
5056 ++ ++ r +++ +++ +++ ++ +
5095 +++ ++ r +++ ++ ++ ++ +
F (aa 392–414)
5195 + +++ r +++ ++ ++ ++ +
This table summarizes the IHC characteristics of the new MAbs described here.
They are identified by the numbers in the first column under A-F. The aa numbers
in parenthesis indicates the different protein domains within which the epitopes
reside that are recognized by these new MAbs. New abbreviations: Nuclei = Normal
endogenous TDP-43 staining; LMN= lower motor neuron cytoplasmic
inclusions, r = rare.
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Here we describe the generation and characterization
of several novel TDP-43 specific MAbs that recognize
epitopes distributed over the entire length of TDP-43
(Figure 1, Table 1) most of which are useful for immu-
noprecipitation and IB methods, as well as for use as
capture or detection MAbs in an ELISA assay in addition
to being effective in ICC and IHC studies. Notably, using
MAb 205 in a sandwich ELISA as the capture antibody,
we were able to detect human rTDP-43 at a lower limit of
25 pg/ml (Additional file 1: Figure S1). Moreover, we also
identified a subset of 7 MAbs that preferentially detect
human TDP-43 and not mouse TDP-43 while we showed
that 11 of these new MAbs detect both human and mouse
TDP-43 with equal robustness. Further, using these new
MAbs, we confirm previous results [13] showing a pre-
dominance of CTF in neocortical TDP-43 inclusions of
FTLD-TDP brains and full-length TDP-43 in the spinal
cord of ALS spinal cord (Figure 3). Remarkably, we identi-
fied a unique MAb (138) that binds to an epitope in the
RRM2 region that shows a preferential reactivity for
pathological TDP-43 inclusions and minimal or no rec-
ognition of normal nuclear TDP-43, similar to diseasespecific phospho-TDP-43 specific MAbs such as the
p409/410 MAb (Figure 4).
Since mouse TDP-43 shares 96% identity with the
human protein, it is not uncommon for antibodies made
against human TDP-43 to react with the mouse protein.
Surprisingly, in this study we identified 7 MAbs that pref-
erentially recognize human TDP-43, 6 of which bind to
an epitope in regions downstream of aa 261. These MAbs
are all human specific on IHC, but have varying immuno-
reactivity on IB to mouse TDP-43, from none detected
to ~30% cross-reactivity. The varying reactivity of these
novel MAbs to mouse TDP-43 most likely reflects under-
lying differences in aa sequence between human and
mouse TDP-43. Thus, these novel and relatively human-
specific TDP-43 MAbs will be very useful for studies of
transgenic animal models of TDP-43 proteinopathies,
including differentiating mouse versus human TDP-43
CTF that accumulate in pathologic inclusions.
Our IHC studies in human ALS and FTLD-TDP tissues
with these novel MAbs suggests they may provide insights
into the pathophysiology of TDP-43 misfolding and aggre-
gation in human disease. First, our results reinforce previ-
ous findings [13] of a predominance of CTF in neocortical
inclusions in FTLD-TDP, confirmed by minimal reactivity
of our novel N-terminus specific MAbs (i.e. regions A-B)
with brain TDP-43 pathology. Interestingly, MAb 211,
which is specific for the extreme N-terminus (Region A),
did not detect significant neocortical pathology while
MAb 5031 (Region B) detected rare to low levels of
neocortical pathology (Figure 3). Furthermore, MAb
5031 did not appear to favor the detection of a particu-
lar cell type (i.e. oligodendrocyte, astrocyte, neurons)
or cellular inclusions type (i.e. NCI, DN, etc.) suggest-
ing the lack of alternative processing of pathological
TDP-43 within different cell types in the neocortex of
FTLD-TDP brains. However, the cause of preferential
accumulation of full-length TDP-43 into LMN neuron
and glial inclusions in the spinal cord of ALS remains
unclear.
IB analysis of human brain urea extracts also showed
that the Nt MAbs had limited immunoreactivity for the
pathological biochemical features of FTLD-TDP. MAb
5031 detected the 43 kD band with similar sensitivity as
the Ct MAb 5056; however, MAb 5031 failed to detect
the Ct fragment, as well as the 45 kD band and the high
MW smear. This finding is consistent with our previously
developed Nt-pAb, which had much less immunoreactiv-
ity toward the pathological TDP-43 on IB when compared
to the Ct-pAb [13]. It is possible that conformational
changes in pathological TDP-43 render the Nt epitope
inaccessible to the antibody by immunoblotting. How-
ever, we cannot rule out the possibility that the majority of
protein species in the 45 kD band and the high MW
smear might not be full length TDP-43.
Figure 3 IHC and IB properties of new N- and C-terminal specific anti-TDP-43 MAbs. N-terminal specific MAb 5031 reacts with spinal cord
ALS TDP-43 pathology (a) with minimal detection of FTLD cortical TDP-43 pathology (arrow, c), while MAb 5056 shows robust reactivity for both
spinal cord (b) and cortical TDP-43 inclusions (arrows, d). Consistent with previous studies [13], immunoblot analysis shows that MAb 5031 detects
full-length but not the CTF of TDP-43 (e), while C-terminal specific MAb 5056 recognizes both (f). Scale bar = 100 μm.
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beyond towards the C-terminus of TDP-43 (i.e. Regions
C-F) showed robust reactivity for neocortical TDP-43
pathology across FTLD-TDP subtypes and ALS spinal
cord inclusions. These MAbs directed against epitopes in
the mid- and C-terminus of TDP-43 detected a moderate
to abundant normal nuclear TDP-43 with the exception
of MAb 138 (Region C) (Figure 4). MAb 138 has a
higher affinity for pathological TDP-43 similar to the
pathology-specific MAb p409/410. MAb 5060 was also
mapped to Region C, but did not share this unique
IHC characteristic with MAb 138. It is unlikely that the
2 MAbs have identical epitope within Region C, which
spans 79 aa. Thus, further epitope mapping is needed
to determine their specific epitopes within this regionand clarify the discordant nature of the IHC reactivity
between these MAbs.
There are several possible explanations for the unique
IHC staining by MAb 138. First, there is a disease-specific
pathological modification to one or more aa within the
epitope recognized by MAb 138, but this seems unlikely
as all these novel MAbs were generated using un-modified
human rTDP-43. Second, a recent report suggests that
the RRM2 region can undergo self-association when
interacting with nucleic acids and this could alter the
conformation of TDP-43 or the accessibility of the epitope
recognized by MAb 138 [26]. Finally, it is possible that
under physiological conditions the MAb 138 specific
epitope may be buried or bound to nucleic acids and
not be accessible to the antibody when present normally
Figure 4 Preferential recognition of pathological TDP-43 by MAb 138. MAb 138 robustly detects pathological TDP-43 inclusions (arrows)
with no or very minimal nuclear staining in FTLD temporal cortex (a) and little recognition of normal nuclear TDP-43 in human control dentate
gyrus (e), similar to previously described antibodies specific for phospho TDP-43 (b, f). In contrast MAb 5060, the epitope for which lies within aa
182–261, and MAb 5195 which detects an epitope contained within aa 394–414, recognize both pathological TDP-43 inclusions (arrows) and
normal nuclear TDP-43 (asterisks) in FTLD temporal cortex (c,d) and control dentate gyrus (g,h). Scale bar = 50 μm.
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inclusions. Of note, MAb 138 does detect the normal
nuclear TDP-43 in QBI293 cells by ICC (Table 2), albeit to
a much less degree or intensity than the other MAbs re-
ported in our study (data not shown) and most published
pan-TDP-43 antibodies. Our previous findings that TDP-
43 could be extracted biochemically with low-stringency
buffers from cultured cells [27], but was only extractable
with high-stringency detergent-containing buffer from CNS
tissue [1], supports a potential structural difference between
nuclear TDP-43 in CNS and cultured cells. Thus, the slight
immunoreactivity of MAb 138 with non-pathological TDP-
43 in non-neuronal cell culture is difficult to interpret
precisely at this time, but we will continue to characterize
the basis for its preferential recognition of pathological
TDP-43 in a large comprehensive neuropathological survey
and further neuronal culture experiments.
Protein misfolding and prion-like spread of neurode-
generative disease proteins has emerged in the forefront of
research for drug-development in FTLD-TDP and ALS
[28,29]. Although TDP-43 transgenic mouse models with
cytoplasmic TDP-43 accumulations that recapitulate clin-
ical and pathological phenotypes of the human disease
remain to be developed, novel MAbs such as those
reported here will be critical to evaluate the sequential
deposition of pathological TDP-43 for pre-clinical evalua-
tions of novel therapeutics focused on TDP-43 aggregation
as well as for use as potential immune therapies. Finally,
there is an urgent need for FTLD-TDP/ALS-specific bio-
markers [30], and ELISAs that are able to reliably measure
CSF and/or plasma levels of TDP-43 will be useful not onlyfor diagnosis, but also for monitoring responses to disease
modifying therapies for FTLD-TDP, ALS and other TDP-
43 proteinopathies [31]. Hence, we expect that the panel
of novel MAbs described here will be informative tools
for future patient oriented and experimental studies of
TDP-43 proteinopathies.
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